Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma
- Autores
- Sterle, Helena Andrea; Cayrol, Maria Florencia; Debernardi, Maria Mercedes; Gonzalez, Gonzalo; Cremaschi, Graciela Alicia
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- Melanoma (ME) is the most severe type of skin cancer and despiteimmune checkpoint inhibitors provide exceptionally durable responses,only a limited number of patients benefit from it, makingcrucial the study of new compounds for ME treatment. Thyroid hormones(TH) influence tumor progression by direct actions on cancercells, tumor microenvironment and antitumor immunity. Our first aimwas to evaluate TH effect on the proliferation of human (A375 andWM35) and mouse (B16F10 and B16F1) ME cells. We found thatphysiological levels of TH induce 15 to 35% ME cell proliferation(p<0.05 vs control). Moreover, cilengitide, a selective inhibitor of theTH membrane receptor (mTR) αvβ3 integrin, not only prevents theproliferative effect of TH, but also inhibits the basal viability of MEcells (*p<0.05 vs vehicle * p<0.05 vs TH). Additionally, the expressionof both integrins was found to be present on ME patient?s samplesfrom the TCGA-SKCM project, indicating that the mTR couldbe a possible target to improve ME therapy. We next evaluated theeffect of thyroid status on ME cells growing in vivo in a syngeneicmouse model. For this, C57Bl/6 mice were subcutaneously inoculatedwith B16F1 cells after the treatment with thyroxine (12mg/l,30 days) or propylthiouracil (500mg/l, 15 days) in the drinking waterto obtain hyperthyroid (hyper) and hypothyroid (hypo) mice. Hypermice showed increased tumor growth rate compared to controls andhypo mice (p<0.05). To further analyze the effect of thyroid statuson the anti-ME immune response we evaluated the distribution ofimmune subsets in secondary lymphoid organs from tumor-bearingmice. We observed an increased percentage of NK cells (p<0.05)and increased cytotoxic T lymphocyte activity (p<0.05) but also increasedproportion of MDSC (p<0.05) in spleens from hyper mice. Our results suggest that TH positively regulate ME cell proliferationthrough αvβ3 integrin and are also involved in the systemic anti-MEimmune response.
Fil: Sterle, Helena Andrea. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cayrol, Maria Florencia. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Debernardi, Maria Mercedes. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Gonzalez, Gonzalo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cremaschi, Graciela Alicia. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina
LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunió Anual de La Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas
Argentina
Sociedad Argentina de Inmunología
Sociedad Argentina de Investigación Clínica
Asociación Argentina de Farmacología Experimental
Sociedad Argentina de Nanomedicinas - Materia
-
THYROID HORMONES
MALANOMA
PROLIFERATION
ANTITUMOR IMMUNITY - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/280711
Ver los metadatos del registro completo
| id |
CONICETDig_e69d4c1160b0d203f0b324c68b0353e5 |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/280711 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Thyroid hormones regulate cell proliferation and antitumor immunity in MelanomaSterle, Helena AndreaCayrol, Maria FlorenciaDebernardi, Maria MercedesGonzalez, GonzaloCremaschi, Graciela AliciaTHYROID HORMONESMALANOMAPROLIFERATIONANTITUMOR IMMUNITYhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Melanoma (ME) is the most severe type of skin cancer and despiteimmune checkpoint inhibitors provide exceptionally durable responses,only a limited number of patients benefit from it, makingcrucial the study of new compounds for ME treatment. Thyroid hormones(TH) influence tumor progression by direct actions on cancercells, tumor microenvironment and antitumor immunity. Our first aimwas to evaluate TH effect on the proliferation of human (A375 andWM35) and mouse (B16F10 and B16F1) ME cells. We found thatphysiological levels of TH induce 15 to 35% ME cell proliferation(p<0.05 vs control). Moreover, cilengitide, a selective inhibitor of theTH membrane receptor (mTR) αvβ3 integrin, not only prevents theproliferative effect of TH, but also inhibits the basal viability of MEcells (*p<0.05 vs vehicle * p<0.05 vs TH). Additionally, the expressionof both integrins was found to be present on ME patient?s samplesfrom the TCGA-SKCM project, indicating that the mTR couldbe a possible target to improve ME therapy. We next evaluated theeffect of thyroid status on ME cells growing in vivo in a syngeneicmouse model. For this, C57Bl/6 mice were subcutaneously inoculatedwith B16F1 cells after the treatment with thyroxine (12mg/l,30 days) or propylthiouracil (500mg/l, 15 days) in the drinking waterto obtain hyperthyroid (hyper) and hypothyroid (hypo) mice. Hypermice showed increased tumor growth rate compared to controls andhypo mice (p<0.05). To further analyze the effect of thyroid statuson the anti-ME immune response we evaluated the distribution ofimmune subsets in secondary lymphoid organs from tumor-bearingmice. We observed an increased percentage of NK cells (p<0.05)and increased cytotoxic T lymphocyte activity (p<0.05) but also increasedproportion of MDSC (p<0.05) in spleens from hyper mice. Our results suggest that TH positively regulate ME cell proliferationthrough αvβ3 integrin and are also involved in the systemic anti-MEimmune response.Fil: Sterle, Helena Andrea. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaFil: Cayrol, Maria Florencia. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaFil: Debernardi, Maria Mercedes. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaFil: Gonzalez, Gonzalo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaFil: Cremaschi, Graciela Alicia. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; ArgentinaLXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunió Anual de La Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de NanomedicinasArgentinaSociedad Argentina de InmunologíaSociedad Argentina de Investigación ClínicaAsociación Argentina de Farmacología ExperimentalSociedad Argentina de NanomedicinasFundación Revista Medicina2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/280711Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunió Anual de La Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 225-225CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol81-21/s3/Mv81s3.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-02-06T12:43:50Zoai:ri.conicet.gov.ar:11336/280711instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-02-06 12:43:50.572CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma |
| title |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma |
| spellingShingle |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma Sterle, Helena Andrea THYROID HORMONES MALANOMA PROLIFERATION ANTITUMOR IMMUNITY |
| title_short |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma |
| title_full |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma |
| title_fullStr |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma |
| title_full_unstemmed |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma |
| title_sort |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma |
| dc.creator.none.fl_str_mv |
Sterle, Helena Andrea Cayrol, Maria Florencia Debernardi, Maria Mercedes Gonzalez, Gonzalo Cremaschi, Graciela Alicia |
| author |
Sterle, Helena Andrea |
| author_facet |
Sterle, Helena Andrea Cayrol, Maria Florencia Debernardi, Maria Mercedes Gonzalez, Gonzalo Cremaschi, Graciela Alicia |
| author_role |
author |
| author2 |
Cayrol, Maria Florencia Debernardi, Maria Mercedes Gonzalez, Gonzalo Cremaschi, Graciela Alicia |
| author2_role |
author author author author |
| dc.subject.none.fl_str_mv |
THYROID HORMONES MALANOMA PROLIFERATION ANTITUMOR IMMUNITY |
| topic |
THYROID HORMONES MALANOMA PROLIFERATION ANTITUMOR IMMUNITY |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Melanoma (ME) is the most severe type of skin cancer and despiteimmune checkpoint inhibitors provide exceptionally durable responses,only a limited number of patients benefit from it, makingcrucial the study of new compounds for ME treatment. Thyroid hormones(TH) influence tumor progression by direct actions on cancercells, tumor microenvironment and antitumor immunity. Our first aimwas to evaluate TH effect on the proliferation of human (A375 andWM35) and mouse (B16F10 and B16F1) ME cells. We found thatphysiological levels of TH induce 15 to 35% ME cell proliferation(p<0.05 vs control). Moreover, cilengitide, a selective inhibitor of theTH membrane receptor (mTR) αvβ3 integrin, not only prevents theproliferative effect of TH, but also inhibits the basal viability of MEcells (*p<0.05 vs vehicle * p<0.05 vs TH). Additionally, the expressionof both integrins was found to be present on ME patient?s samplesfrom the TCGA-SKCM project, indicating that the mTR couldbe a possible target to improve ME therapy. We next evaluated theeffect of thyroid status on ME cells growing in vivo in a syngeneicmouse model. For this, C57Bl/6 mice were subcutaneously inoculatedwith B16F1 cells after the treatment with thyroxine (12mg/l,30 days) or propylthiouracil (500mg/l, 15 days) in the drinking waterto obtain hyperthyroid (hyper) and hypothyroid (hypo) mice. Hypermice showed increased tumor growth rate compared to controls andhypo mice (p<0.05). To further analyze the effect of thyroid statuson the anti-ME immune response we evaluated the distribution ofimmune subsets in secondary lymphoid organs from tumor-bearingmice. We observed an increased percentage of NK cells (p<0.05)and increased cytotoxic T lymphocyte activity (p<0.05) but also increasedproportion of MDSC (p<0.05) in spleens from hyper mice. Our results suggest that TH positively regulate ME cell proliferationthrough αvβ3 integrin and are also involved in the systemic anti-MEimmune response. Fil: Sterle, Helena Andrea. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina Fil: Cayrol, Maria Florencia. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina Fil: Debernardi, Maria Mercedes. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina Fil: Gonzalez, Gonzalo. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina Fil: Cremaschi, Graciela Alicia. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Instituto de Investigaciones Biomédicas. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas; Argentina LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunió Anual de La Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas Argentina Sociedad Argentina de Inmunología Sociedad Argentina de Investigación Clínica Asociación Argentina de Farmacología Experimental Sociedad Argentina de Nanomedicinas |
| description |
Melanoma (ME) is the most severe type of skin cancer and despiteimmune checkpoint inhibitors provide exceptionally durable responses,only a limited number of patients benefit from it, makingcrucial the study of new compounds for ME treatment. Thyroid hormones(TH) influence tumor progression by direct actions on cancercells, tumor microenvironment and antitumor immunity. Our first aimwas to evaluate TH effect on the proliferation of human (A375 andWM35) and mouse (B16F10 and B16F1) ME cells. We found thatphysiological levels of TH induce 15 to 35% ME cell proliferation(p<0.05 vs control). Moreover, cilengitide, a selective inhibitor of theTH membrane receptor (mTR) αvβ3 integrin, not only prevents theproliferative effect of TH, but also inhibits the basal viability of MEcells (*p<0.05 vs vehicle * p<0.05 vs TH). Additionally, the expressionof both integrins was found to be present on ME patient?s samplesfrom the TCGA-SKCM project, indicating that the mTR couldbe a possible target to improve ME therapy. We next evaluated theeffect of thyroid status on ME cells growing in vivo in a syngeneicmouse model. For this, C57Bl/6 mice were subcutaneously inoculatedwith B16F1 cells after the treatment with thyroxine (12mg/l,30 days) or propylthiouracil (500mg/l, 15 days) in the drinking waterto obtain hyperthyroid (hyper) and hypothyroid (hypo) mice. Hypermice showed increased tumor growth rate compared to controls andhypo mice (p<0.05). To further analyze the effect of thyroid statuson the anti-ME immune response we evaluated the distribution ofimmune subsets in secondary lymphoid organs from tumor-bearingmice. We observed an increased percentage of NK cells (p<0.05)and increased cytotoxic T lymphocyte activity (p<0.05) but also increasedproportion of MDSC (p<0.05) in spleens from hyper mice. Our results suggest that TH positively regulate ME cell proliferationthrough αvβ3 integrin and are also involved in the systemic anti-MEimmune response. |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Reunión Journal http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
| status_str |
publishedVersion |
| format |
conferenceObject |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/280711 Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunió Anual de La Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 225-225 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/280711 |
| identifier_str_mv |
Thyroid hormones regulate cell proliferation and antitumor immunity in Melanoma; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunió Anual de La Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 225-225 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol81-21/s3/Mv81s3.pdf |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
| dc.coverage.none.fl_str_mv |
Nacional |
| dc.publisher.none.fl_str_mv |
Fundación Revista Medicina |
| publisher.none.fl_str_mv |
Fundación Revista Medicina |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1856403260781363200 |
| score |
13.106097 |